KRAS Amplification

Loading variant…

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Cutaneous Melanoma1
KRAS Amplification	Carboplatin + Docetaxel + SorafenibCombination	Predictive	B	Supports Sensitivity Response	2	accepted	EID1497 Retrospective analysis of somatic mutations and copy number changes in 119 patients treated with carboplatin, paclitaxel, ± sorafenib (CPS) in the E2603 trial. CPS therapy was associated with improved… (full text at CIViC) PMID 26307133 · Wilson et al., 2016 · Open in CIViC	civic
Lung Non-Small Cell Carcinoma2
KRAS Amplification	Crizotinib	Predictive	C	Supports Resistance	2	submitted	EID9116 To characterize crizotinib resistant tumors, three patient cases with established MET exon 14 (METex14) mutant non-small cell lung cancer (NSCLC) samples were all found to have gained amplification of…

Molecular profile

Therapy

Type

Level

Direction · significance

Rating (1–5)

Status

Evidence

Source

Cutaneous Melanoma1

KRAS Amplification

Carboplatin + Docetaxel + SorafenibCombination

Predictive

Supports Sensitivity Response

accepted

EID1497

Retrospective analysis of somatic mutations and copy number changes in 119 patients treated with carboplatin, paclitaxel, ± sorafenib (CPS) in the E2603 trial. CPS therapy was associated with improved… (full text at CIViC)

PMID 26307133 · Wilson et al., 2016 · Open in CIViC

civic

Lung Non-Small Cell Carcinoma2

KRAS Amplification

Crizotinib

Predictive

Supports Resistance

submitted

EID9116

To characterize crizotinib resistant tumors, three patient cases with established MET exon 14 (METex14) mutant non-small cell lung cancer (NSCLC) samples were all found to have gained amplification of…

Malignant Colorectal Neoplasm2
KRAS Amplification	Cetuximab + EncorafenibCombination	Predictive	B	Supports Resistance	3	submitted	EID2928 Paired pre-treatment and post-progression tumor biopsies from BRAF-mutant CRC patients treated with RAF inhibitor combinations were analyzed. Alterations in MAPK pathway genes were found in resistant … (full text at CIViC) PMID 25673644 · Ahronian et al., 2015 · Open in CIViC	civic
KRAS Amplification	Cetuximab + Panitumumab	Predictive	B	Supports Resistance	3	submitted	EID7105 Screening of 1,039 CRC samples to assess the prevalence of KRAS amplification and the role of this genetic alteration on the sensitivity to anti EGFR therapies. KRAS amplification was mutually exclusi… (full text at CIViC) PMID 23404247 · Valtorta et al., 2013 · Open in CIViC	civic

Malignant Colorectal Neoplasm2

KRAS Amplification

Cetuximab + EncorafenibCombination

Predictive

Supports Resistance

submitted

EID2928

Paired pre-treatment and post-progression tumor biopsies from BRAF-mutant CRC patients treated with RAF inhibitor combinations were analyzed. Alterations in MAPK pathway genes were found in resistant … (full text at CIViC)

PMID 25673644 · Ahronian et al., 2015 · Open in CIViC

civic

KRAS Amplification

Cetuximab + Panitumumab

Predictive

Supports Resistance

submitted

EID7105

Screening of 1,039 CRC samples to assess the prevalence of KRAS amplification and the role of this genetic alteration on the sensitivity to anti EGFR therapies. KRAS amplification was mutually exclusi… (full text at CIViC)

PMID 23404247 · Valtorta et al., 2013 · Open in CIViC

civic

Malignant Endometrial Neoplasm1
KRAS Amplification	(prognostic)	Prognostic	B	Supports Poor Outcome	3	accepted	EID5836 In this study, KRAS gain (KRAS/CEP12q ratio >1 and <2) or amplification (ratio >2) was detected in 3% (13 of 414) of the primary endometrial carcinomas investigated. Presence of KRAS gain or amplifica… (full text at CIViC) PMID 23099803 · Birkeland et al., 2012 · Open in CIViC	civic

Malignant Endometrial Neoplasm1

KRAS Amplification

(prognostic)

Prognostic

Supports Poor Outcome

accepted

EID5836

In this study, KRAS gain (KRAS/CEP12q ratio >1 and <2) or amplification (ratio >2) was detected in 3% (13 of 414) of the primary endometrial carcinomas investigated. Presence of KRAS gain or amplifica… (full text at CIViC)

PMID 23099803 · Birkeland et al., 2012 · Open in CIViC

civic

Melanoma1
KRAS Amplification	Vemurafenib	Predictive	D	Supports Resistance	2	accepted	EID6317 In vitro studies of M229 (a human melanoma cell line) endogenously expressing wildtype KRAS and BRAF V600E (a known BRAF sensitizing mutation) found that cells induced to stably over-express wildtype … (full text at CIViC) PMID 24265155 · Shi et al., 2014 · Open in CIViC	civic

Melanoma1

KRAS Amplification

Vemurafenib

Predictive

Supports Resistance

accepted

EID6317

In vitro studies of M229 (a human melanoma cell line) endogenously expressing wildtype KRAS and BRAF V600E (a known BRAF sensitizing mutation) found that cells induced to stably over-express wildtype … (full text at CIViC)

PMID 24265155 · Shi et al., 2014 · Open in CIViC

civic

Solid Tumors, Advanced1unmapped disease
KRAS G12C OR KRAS G12D OR KRAS G13D OR RET M918T OR KRAS G12A OR KRAS G12V OR KRAS G12R OR KRAS Amplification OR KRAS G12S OR KRAS G13R OR KRAS G12P	Sorafenib	Predictive	B	Supports Sensitivity Response	3	submitted	EID12700 In the randomized discontinuation Phase II MOST-Plus trial of advanced/metastatic solid tumors with sorafenib-targeted somatic alterations (NCT02029001; n = 35 randomized; KRAS G12A/C/D/P/R/S/V n = 29… (full text at CIViC) PMID 37444551 · Trédan et al., 2023 · Open in CIViC	civic

Solid Tumors, Advanced1unmapped disease

KRAS G12C OR KRAS G12D OR KRAS G13D OR RET M918T OR KRAS G12A OR KRAS G12V OR KRAS G12R OR KRAS Amplification OR KRAS G12S OR KRAS G13R OR KRAS G12P

Sorafenib

Predictive

Supports Sensitivity Response

submitted

EID12700

In the randomized discontinuation Phase II MOST-Plus trial of advanced/metastatic solid tumors with sorafenib-targeted somatic alterations (NCT02029001; n = 35 randomized; KRAS G12A/C/D/P/R/S/V n = 29… (full text at CIViC)

PMID 37444551 · Trédan et al., 2023 · Open in CIViC

civic

Evidence by cancer (8 items)

Clinical significance (0)